Zentalis Pharmaceuticals, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $0.0 | $67.4 | $0.0 | $0.0 | — |
| Operating income | -$152.8 | -$191.2 | -$299.5 | -$227.3 | -$216.5 |
| Net income | -$137.1 | -$165.8 | -$292.2 | -$236.8 | -$158.7 |
| Cash Flow Statement | |||||
| Free cash flow | -$125.2 | -$171.1 | -$208.4 | -$166.3 | -$160.2 |
| Share repurchases | $10.0 | $0.0 | $0.0 | — | — |
Shares outstanding 71.2M · Free float 62.6%
Annual filing data through FY ended December 31, 2025; float as of July 15, 2026.